Cordis Endovascular's vena cava filter gets FDA go-ahead:
This article was originally published in Clinica
Cordis Endovascular, a Johnson & Johnson company, has received US FDA 510(k) clearance to market its 6F TRAPEASE permanent vena cava filter. Designed to prevent pulmonary embolism, the 6 French delivery system provides flexibility and support, minimising patient trauma and insertion site thrombosis. It has a symmetrical double-basket design, providing two levels of filtering and is the smallest, least invasive permanent vena cava filter available, claims the Warren, New Jersey-based company.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.